Provides with respect to the advisory board created to recommend new treatments for rare cancers (OR NO IMPACT See Note)

HB 761 amends Louisiana Revised Statutes section 22:1076.1 to modify the composition and reporting procedures of the advisory board for rare cancer treatments within the Department of Insurance. The bill increases the number of oncologists specializing in rare cancer treatments on the board from two to four members, thereby expanding the total board membership from fifteen to seventeen members. Additionally, the bill extends the deadline for submitting written reports of the board's findings from thirty days to forty-five days following each quarterly meeting and redirects those reports to be submitted specifically to the House Committee on Insurance and the Senate Committee on Insurance rather than to the legislature generally. The statutory framework for the board's authority to review and provide medical recommendations for new rare cancer treatments remains substantively unchanged.

The practical impact of these amendments affects the Louisiana advisory board for rare cancer treatments and the various stakeholder organizations it represents. The expansion to four oncologists specializing in rare cancer treatments enhances the clinical expertise dedicated to evaluating new treatment options and ensures that physicians with direct experience treating uncommon malignancies have greater representation in the board's deliberations. Government agencies including the Department of Insurance, Department of Health, and the office of the Surgeon General will continue their participation alongside representatives from major medical institutions such as LSU Health Sciences Center at New Orleans, Tulane Medical School, and Xavier Ochsner College of Medicine. The extended reporting deadline provides the advisory board an additional two weeks to compile findings and prepare formal documentation, while the specification of target committees streamlines the legislative oversight process by directing reports to the committees with direct jurisdiction over insurance and health matters.

The amendments operate within the existing legal framework established by Louisiana Revised Statutes title 22, which governs insurance regulation in Louisiana. The Department of Insurance Commissioner retains authority to promulgate administrative rules and regulations necessary to implement these provisions in accordance with the Administrative Procedure Act. The creation of this advisory board reflects Louisiana's statutory approach to evaluating emerging cancer treatments through a structured multidisciplinary process involving medical professionals, government officials, and representatives of health insurance plans and research institutions. The reporting requirement establishes a mechanism for legislative oversight of the board's work while the composition requirements ensure balanced representation of medical, administrative, and institutional interests in the evaluation of rare cancer treatments.